Abstract 203P
Background
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Certain etiologies such as hepatotropic viruses, alcohol, and metabolic dysfunction-associated fatty liver disease (MAFLD) contribute to the incidence of HCC. The aim of this study was to evaluate the impact of etiology on overall survival in Latin-American patients with HCC.
Methods
Retrospective, observational study. Included patients with HCC treated at the National Cancer Institute between 2008-2021. Statistical analysis: X2 and t-test, Kaplan Meier, Log Rank, and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.
Results
89 patients with HCC were included. Most of the patients were male (n=60, 67.4) with a median age of 66 years (17 - 87), according to etiology, MAFLD represents 61.8% (n=55) and non-MAFLD 38.2% (n=34) (alcoholic 24.7%, viral associated 12.4% and other 1.1%). Ultrasound-guided percutaneous biopsy was performed in 77.5% (n=69) for diagnosis and the histological subtype was poorly differentiated carcinoma (n=45, 50.6%). Eastern Cooperative Oncology Group (ECOG) performance status 1 represents 79.8% (n=71), CHILD-PUGH A5 represents 57.3% (n=51) and ALBI grade 2, 60.7% (n=54), Regarding treatment, 48.3% (n=43) of patients received sorafenib, which is the most common line of treatment. An OS analysis was performed considering etiology, patients with MAFLD reported a median OS of 32 months versus 16 months for non-MAFLD (p=0.012, HR 0.27, 95% CI 0.10-0.70). Besides, a subanalysis was performed considering only patients treated with sorafenib, comparing etiology, MAFLD patients reported a median OS of 35 months versus 16 months for non-MAFLD (p=0.071, HR 0.80, 95% CI 0.42-1.53). At Cox Regression analysis, MAFLD etiology remained as predictor factor of OS, (HR: 0.45; 95% Cl 0.23-0.86 p=0.019).
Conclusions
MAFLD has been identified as an independent prognostic factor for overall survival in patients with HCC. Moreover, a clinical tendency of a better OS was observed for patients treated with sorafenib. Thereby suggesting the role of the etiology in the selection of patients for tyrosine kinase treatment. Sorafenib may be a suitable agent for patients with MAFLD-HCC.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.